The drug discovery and development company Exelixis will be laying off 270 people, or 40 percent of its workforce, reports the San Francisco Business Times. The company's drug discovery group will bear the brunt of the cuts. The company says that having lower compensation, lab supplies and clinical trial costs will save it $90 million through 2011.